193 related articles for article (PubMed ID: 16721513)
1. P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?).
Orlowski S; Martin S; Escargueil A
Cell Mol Life Sci; 2006 May; 63(9):1038-59. PubMed ID: 16721513
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol-Depletion-Induced Membrane Repair Carries a Raft Conformer of P-Glycoprotein to the Cell Surface, Indicating Enhanced Cholesterol Trafficking in MDR Cells, Which Makes Them Resistant to Cholesterol Modifications.
Gutay-Tóth Z; Gellen G; Doan M; Eliason JF; Vincze J; Szente L; Fenyvesi F; Goda K; Vecsernyés M; Szabó G; Bacso Z
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569709
[TBL] [Abstract][Full Text] [Related]
3. SCP-2/SCP-x gene ablation alters lipid raft domains in primary cultured mouse hepatocytes.
Atshaves BP; McIntosh AL; Payne HR; Gallegos AM; Landrock K; Maeda N; Kier AB; Schroeder F
J Lipid Res; 2007 Oct; 48(10):2193-211. PubMed ID: 17609524
[TBL] [Abstract][Full Text] [Related]
4. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.
Garrigues A; Escargueil AE; Orlowski S
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10347-52. PubMed ID: 12145328
[TBL] [Abstract][Full Text] [Related]
5. Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities.
Bucher K; Besse CA; Kamau SW; Wunderli-Allenspach H; Krämer SD
Pharm Res; 2005 Mar; 22(3):449-57. PubMed ID: 15835751
[TBL] [Abstract][Full Text] [Related]
6. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
Ghetie MA; Crank M; Kufert S; Pop I; Vitetta E
J Immunother; 2006; 29(5):536-44. PubMed ID: 16971809
[TBL] [Abstract][Full Text] [Related]
7. An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line.
Ghetie MA; Marches R; Kufert S; Vitetta ES
Blood; 2004 Jul; 104(1):178-83. PubMed ID: 15001473
[TBL] [Abstract][Full Text] [Related]
8. P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains.
Radeva G; Perabo J; Sharom FJ
FEBS J; 2005 Oct; 272(19):4924-37. PubMed ID: 16176266
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment.
Modok S; Heyward C; Callaghan R
J Lipid Res; 2004 Oct; 45(10):1910-8. PubMed ID: 15258203
[TBL] [Abstract][Full Text] [Related]
10. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells.
Zhong Y; Hennig B; Toborek M
J Cereb Blood Flow Metab; 2010 Mar; 30(3):522-33. PubMed ID: 19794400
[TBL] [Abstract][Full Text] [Related]
11. SNARE proteins and 'membrane rafts'.
Lang T
J Physiol; 2007 Dec; 585(Pt 3):693-8. PubMed ID: 17478530
[TBL] [Abstract][Full Text] [Related]
12. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
13. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway.
Mendez AJ; Lin G; Wade DP; Lawn RM; Oram JF
J Biol Chem; 2001 Feb; 276(5):3158-66. PubMed ID: 11073951
[TBL] [Abstract][Full Text] [Related]
14. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function.
Butchbach ME; Tian G; Guo H; Lin CL
J Biol Chem; 2004 Aug; 279(33):34388-96. PubMed ID: 15187084
[TBL] [Abstract][Full Text] [Related]
15. Sterol carrier protein-2 selectively alters lipid composition and cholesterol dynamics of caveolae/lipid raft vs nonraft domains in L-cell fibroblast plasma membranes.
Atshaves BP; Gallegos AM; McIntosh AL; Kier AB; Schroeder F
Biochemistry; 2003 Dec; 42(49):14583-98. PubMed ID: 14661971
[TBL] [Abstract][Full Text] [Related]
16. The sensing of membrane microdomains based on pore-forming toxins.
Skočaj M; Bakrač B; Križaj I; Maček P; Anderluh G; Sepčić K
Curr Med Chem; 2013; 20(4):491-501. PubMed ID: 23244522
[TBL] [Abstract][Full Text] [Related]
17. Membrane microdomains, caveolae, and caveolar endocytosis of sphingolipids.
Cheng ZJ; Singh RD; Marks DL; Pagano RE
Mol Membr Biol; 2006; 23(1):101-10. PubMed ID: 16611585
[TBL] [Abstract][Full Text] [Related]
18. Lipid rafts: heterogeneity on the high seas.
Pike LJ
Biochem J; 2004 Mar; 378(Pt 2):281-92. PubMed ID: 14662007
[TBL] [Abstract][Full Text] [Related]
19. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
20. Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains.
Drobnik W; Borsukova H; Böttcher A; Pfeiffer A; Liebisch G; Schütz GJ; Schindler H; Schmitz G
Traffic; 2002 Apr; 3(4):268-78. PubMed ID: 11929608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
